Ipca Laboratories Q4 Results: Net profit rises 14% to ₹68 crore; final dividend declared

The company said its consolidated net profit increased by 13.8% year-on-year (YoY) to ₹67.82 crore during the March 2025 quarter. It had reported a net profit of ₹59.59 crore in the corresponding quarter of the previous fiscal year.

During the March 2025 quarter, revenue from operations rose 10.5% YoY to ₹2,247 crore as compared to ₹2,033 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.

Its EBITDA before forex (gain)/loss, other income and exceptional items surged by 35% YoY to ₹409.74 crore from ₹304.59 crore logged in the year-ago period.

EBITDA stands for earnings before interest, taxes, depreciation, and amortisation.

Net profit stood at ₹738 crore for 2024-25 fiscal against ₹547 crore in FY24, up 34.9%.

Revenue rose to ₹8,940 crore for the last fiscal from ₹7,705 crore seen a year ago.

The company said its board has recommended a final dividend of ₹2 per share for the year ended March 31, 2025.

Ipca Laboratories Limited (IPCA) is a fully integrated pharmaceutical company. It is known for manufacturing both formulations and active pharmaceutical ingredients (APIs).

According to the company's website, Ipca Labs is one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s drug regulatory authorities such as UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Ipca Laboratories Q4: Dividend Details

The company said its board has recommended a final dividend of ₹2 per share (200%) for the financial year ended March 31, 2025. This is subject to the approval of the shareholders at the ensuing annual general meeting (AGM). The company has fixed Tuesday, August 5, 2025, as the record date for the members entitlement of final dividend, if it is approved at the AGM.

Ipca Laboratories share price trend

The stock has gained nearly 15% in the past 12 months. However, on a year-to-date (YTD) basis, shares have fallen over 12%. In the past 30 days, the stock has gained over 6.5%.